<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23418527</article-id><article-id pub-id-type="pmc">3571963</article-id><article-id pub-id-type="publisher-id">PONE-D-12-33392</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0056151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Anatomy and Physiology</subject><subj-group><subject>Cardiovascular System</subject><subj-group><subject>Circulatory Physiology</subject></subj-group></subj-group></subj-group><subj-group><subject>Cardiovascular</subject><subj-group><subject>Hemodynamics</subject></subj-group></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Cardiovascular Pharmacology</subject><subject>Drug Interactions</subject></subj-group></subj-group><subj-group><subject>Hematology</subject><subj-group><subject>Hematopoiesis</subject><subject>Heme Synthesis</subject><subject>Red Cells</subject></subj-group></subj-group><subj-group><subject>Nephrology</subject><subj-group><subject>Hemodynamics</subject></subj-group></subj-group><subj-group><subject>Sports and Exercise Medicine</subject></subj-group></subj-group></article-categories><title-group><article-title>Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men</article-title><alt-title alt-title-type="running-head">Hbmass and Running Performance after rHuEpo</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Durussel</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Daskalaki</surname><given-names>Evangelia</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chatterji</surname><given-names>Tushar</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wondimu</surname><given-names>Diresibachew H.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Padmanabhan</surname><given-names>Neal</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Rajan K.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>McClure</surname><given-names>John D.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pitsiladis</surname><given-names>Yannis P.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Medical Physiology, Addis Ababa University, Addis Ababa, Ethiopia</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Zambidis</surname><given-names>Elias T.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Johns Hopkins School of Medicine, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>Yannis.Pitsiladis@glasgow.ac.uk</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: JD YPP. Performed the experiments: JD ED MA TC DHW NP RKP. Analyzed the data: JD MA JDM YPP. Contributed reagents/materials/analysis tools: YPP. Wrote the paper: JD YPP.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>13</day><month>2</month><year>2013</year></pub-date><volume>8</volume><issue>2</issue><elocation-id>e56151</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>5</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Durussel et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Durussel et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb<sub>mass</sub>) and maximal oxygen uptake (<inline-formula><inline-graphic xlink:href="pone.0056151.e001.jpg"/></inline-formula> O<sub>2 max</sub>).</p><sec><title>Purpose</title><p>This study defined the time course of changes in Hb<sub>mass</sub>, <inline-formula><inline-graphic xlink:href="pone.0056151.e002.jpg"/></inline-formula> O<sub>2 max</sub> as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field.</p></sec><sec><title>Methods</title><p>19 trained men received rHuEpo injections of 50 IU&#x02022;kg<sup>&#x02212;1</sup> body mass every two days for 4 weeks. Hb<sub>mass</sub> was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. <inline-formula><inline-graphic xlink:href="pone.0056151.e003.jpg"/></inline-formula> O<sub>2 max</sub> and 3,000 m time trial performance were measured pre, post administration and at the end of the study.</p></sec><sec><title>Results</title><p>Relative to baseline, running performance significantly improved by &#x0223c;6% after administration (10&#x02236;30&#x000b1;1&#x02236;07 min:sec vs. 11&#x02236;08&#x000b1;1&#x02236;15 min:sec, p&#x0003c;0.001) and remained significantly enhanced by &#x0223c;3% 4 weeks after administration (10&#x02236;46&#x000b1;1&#x02236;13 min:sec, p&#x0003c;0.001), while <inline-formula><inline-graphic xlink:href="pone.0056151.e004.jpg"/></inline-formula> O<sub>2 max</sub> was also significantly increased post administration (60.7&#x000b1;5.8 mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup> vs. 56.0&#x000b1;6.2 mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup>, p&#x0003c;0.001) and remained significantly increased 4 weeks after rHuEpo (58.0&#x000b1;5.6 mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup>, p&#x0200a;=&#x0200a;0.021). Hb<sub>mass</sub> was significantly increased at the end of administration compared to baseline (15.2&#x000b1;1.5 g&#x02022;kg<sup>&#x02212;1</sup> vs. 12.7&#x000b1;1.2 g&#x02022;kg<sup>&#x02212;1</sup>, p&#x0003c;0.001). The rate of decrease in Hb<sub>mass</sub> toward baseline values post rHuEpo was similar to that of the increase during administration (&#x02212;0.53 g&#x02022;kg<sup>&#x02212;1</sup>&#x02022;wk<sup>&#x02212;1</sup>, 95% confidence interval (CI) (&#x02212;0.68, &#x02212;0.38) vs. 0.54 g&#x02022;kg<sup>&#x02212;1&#x02022;</sup>wk<sup>&#x02212;1</sup>, CI (0.46, 0.63)) but Hb<sub>mass</sub> was still significantly elevated 4 weeks after administration compared to baseline (13.7&#x000b1;1.1 g&#x02022;kg<sup>&#x02212;1</sup>, p&#x0003c;0.001).</p></sec><sec><title>Conclusion</title><p>Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated <inline-formula><inline-graphic xlink:href="pone.0056151.e005.jpg"/></inline-formula> O<sub>2 max</sub> and Hb<sub>mass</sub>.</p></sec></abstract><funding-group><funding-statement>This study was part of a larger research project supported and funded by World Anti-Doping Agency (08C19YP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Erythropoietin is a glycoprotein hormone produced primarily in the kidney that regulates red blood cell mass by stimulating the survival, proliferation and differentiation of erythrocytic progenitors <xref rid="pone.0056151-Jelkmann1" ref-type="bibr">[1]</xref>. In healthy subjects, administration of recombinant human erythropoietin (rHuEpo) increases haemoglobin concentration not only by the well known increase in red blood cell mass but also by a decrease in plasma volume <xref rid="pone.0056151-Lundby1" ref-type="bibr">[2]</xref>, <xref rid="pone.0056151-Olsen1" ref-type="bibr">[3]</xref>, <xref rid="pone.0056151-Lundby2" ref-type="bibr">[4]</xref>. The decrease in plasma volume, which precedes the increase in red cell mass, appears to be a rapid responding mechanism regulated by the renin-angiotensin-aldosterone system to control haematocrit <xref rid="pone.0056151-Lundby1" ref-type="bibr">[2]</xref>, <xref rid="pone.0056151-Olsen1" ref-type="bibr">[3]</xref>. Theoretically, normal human red blood cells can persist in the circulation for approximately 17 weeks <xref rid="pone.0056151-Franco1" ref-type="bibr">[5]</xref>. However, neocytolysis, the selective hemolysis of young circulating red blood cells which contributes to the regulation of red cell mass, seems to appear during specific conditions that cause a rapid decrease in erythropoietin levels such as spaceflight, high altitude exposure or blood doping <xref rid="pone.0056151-Franco1" ref-type="bibr">[5]</xref>, <xref rid="pone.0056151-Rice1" ref-type="bibr">[6]</xref>, <xref rid="pone.0056151-Rice2" ref-type="bibr">[7]</xref>, <xref rid="pone.0056151-Chang1" ref-type="bibr">[8]</xref>, <xref rid="pone.0056151-Alfrey1" ref-type="bibr">[9]</xref>. Little is known about the time course of these mechanisms post rHuEpo administrations. In this study, heamoglobin mass (Hb<sub>mass</sub>) and related blood volumes were repeatedly determined using the optimized carbon monoxide (CO) rebreathing method <xref rid="pone.0056151-Schmidt1" ref-type="bibr">[10]</xref>, <xref rid="pone.0056151-Durussel1" ref-type="bibr">[11]</xref> pre, during and post rHuEpo administration in healthy trained men.</p><p>Most studies investigating the effects of rHuEpo on exercise performance have used maximal oxygen uptake (<inline-formula><inline-graphic xlink:href="pone.0056151.e006.jpg"/></inline-formula> O<sub>2 max</sub>) tests. However, <inline-formula><inline-graphic xlink:href="pone.0056151.e007.jpg"/></inline-formula> O<sub>2 max</sub> tests alone may be of little help in predicting exercise performance among athletes of similar ability <xref rid="pone.0056151-Noakes1" ref-type="bibr">[12]</xref>, <xref rid="pone.0056151-Shephard1" ref-type="bibr">[13]</xref>, <xref rid="pone.0056151-Costill1" ref-type="bibr">[14]</xref>, <xref rid="pone.0056151-Levine1" ref-type="bibr">[15]</xref>. One study assessed submaximal performance in healthy male subjects and reported improvements of more than 50% in time to exhaustion on a cycle ergometer at a given 80% of <inline-formula><inline-graphic xlink:href="pone.0056151.e008.jpg"/></inline-formula> O<sub>2 max</sub> whereas the increase in <inline-formula><inline-graphic xlink:href="pone.0056151.e009.jpg"/></inline-formula> O<sub>2 max</sub> was approximately 12% <xref rid="pone.0056151-Thomsen1" ref-type="bibr">[16]</xref>. Despite being a very interesting finding which questions the mechanisms by which rHuEpo improves submaximal exercise performance <xref rid="pone.0056151-Noakes2" ref-type="bibr">[17]</xref>, the validity of the time to exhaustion test in assessing human exercise performance has been questioned <xref rid="pone.0056151-Millet1" ref-type="bibr">[18]</xref>. In addition to being more variable than time trial tests <xref rid="pone.0056151-Laursen1" ref-type="bibr">[19]</xref>, time to exhaustion tests are less likely to mimic the exercise performance environment <xref rid="pone.0056151-Millet1" ref-type="bibr">[18]</xref>, <xref rid="pone.0056151-Laursen1" ref-type="bibr">[19]</xref>. There are indeed only minimal occasions where an athlete is required to maintain a constant intensity until volitional exhaustion compared with self-paced exercise <xref rid="pone.0056151-Millet1" ref-type="bibr">[18]</xref>, <xref rid="pone.0056151-Laursen1" ref-type="bibr">[19]</xref>.</p><p>The main purpose of the present study was to investigate the time course of Hb<sub>mass</sub> and related blood parameters as well as changes in running 3,000 m time trial performance following 4 weeks of rHuEpo administration in healthy trained men in order to determine whether the augmented <inline-formula><inline-graphic xlink:href="pone.0056151.e010.jpg"/></inline-formula> O<sub>2 max</sub> observed in laboratory based experiments would translate into actual improvements in running performance in the field.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Ethics Statement</title><p>This study was approved by University of Glasgow Ethics Committee and conformed to the Declaration of Helsinki. All subjects underwent a medical assessment and provided written informed consent to participate. This study was part of a larger research project funded by the World Anti-Doping Agency (WADA).</p></sec><sec id="s2b"><title>Subjects</title><p>Nineteen healthy non-smoking trained men (mean &#x000b1; SD, age: 26.0&#x000b1;4.5 yr, body mass: 74.8&#x000b1;7.9 kg, height: 179.8&#x000b1;5.4 cm) participated in this study. The subjects were regularly engaged in predominantly endurance-based activities such as running, cycling, swimming, triathlon and team sports. The subjects were divided into two groups for exercise performance analysis. The first group included subjects who had a history of running (n&#x0200a;=&#x0200a;10) and the second group included the remaining subjects who were involved in other sporting activities (n&#x0200a;=&#x0200a;9). Subjects were requested to maintain their normal training but abstain from official sporting competition for the duration of the research protocol. One of the subjects in the running group suffered from nasal obstruction and coughing during the study and could not perform the time trials post rHuEpo administration. The running performance data of this subject was excluded from the analyses.</p></sec><sec id="s2c"><title>Experimental Design</title><p>Each subject subcutaneously self-injected 50 IU&#x02022;kg<sup>&#x02212;1</sup> body mass of rHuEpo (NeoRecormon, Roche, Welwyn Garden City, UK) every second day for 4 weeks. Daily oral iron supplementation (&#x0223c; 100 mg of elemental iron, Ferrous Sulphate Tablets, Almus, Barnstaple, UK) was given during the 4 weeks of rHuEpo administration. Venous blood samples from an antecubital vein were obtained in triplicate at baseline (over 2 weeks prior to the first rHuEpo administration), during rHuEpo administration (on days 2, 4, 8, 10, 14, 16, 20, 22, 26, 28) and for 4 weeks after rHuEpo administration (on days 30, 35, 41, 43, 48, 50, 57). All blood samples were taken after 10 min of rest in the supine position <xref rid="pone.0056151-Ahlgrim1" ref-type="bibr">[20]</xref>. Blood samples were homogenized using a roller mixer and then measured in triplicate using a Sysmex XT-2000i (Sysmex UK, Milton Keynes, UK). The mean value of the triplicate was reported. Resting blood pressure and heart rate were recorded three times on both arms in the supine position before blood sampling using an automated cuff oscillometric device (Boso-Medicus, Bosch &#x00026; Sohn GmbH, Jungingen, Germany).</p></sec><sec id="s2d"><title>Measurements of Haemoglobin Mass and Related Blood Volumes</title><p>Hb<sub>mass</sub> was determined in triplicate prior to the first rHuEpo injection and then weekly up to 4 weeks post rHuEpo administration using the optimized CO-rebreathing method as previously described <xref rid="pone.0056151-Schmidt1" ref-type="bibr">[10]</xref>, <xref rid="pone.0056151-Durussel1" ref-type="bibr">[11]</xref>. Briefly, a bolus of chemically pure CO dose of 1.0 mL&#x02022;kg<sup>&#x02212;1</sup> body mass was administered with the first breath through a spirometer and rebreathed for 2 min with 4 L of oxygen. Change in percent carboxyhaemoglobin in venous blood samples from baseline to 8 min after CO administration was measured using a blood gas analyzer (ABL 725, Radiometer, Copenhagen, Denmark). CO concentration was measured using the Pac 7000 Draeger CO-analyzer (Draeger Safety, Northumberland, UK) and an estimated alveolar ventilation of 7.5 l&#x02022;min<sup>&#x02212;1</sup> was used for calculations. Hb<sub>mass</sub> as well as blood, red cell and plasma volume were calculated as previously described elsewhere <xref rid="pone.0056151-Durussel1" ref-type="bibr">[11]</xref>. Blood volume was derived by dividing Hb<sub>mass</sub> by the haemoglobin concentration. Red cell volume was obtained by multiplying blood volume by the haematocrit and plasma volume was then calculated by subtracting red cell volume from blood volume. The typical error of measurement for Hb<sub>mass</sub> calculated from the two first baseline measurements was 1.5% (95% confidence interval (CI) 1.1 to 2.2%). The typical error of measurement for blood, red cell and plasma volume between the two weeks prior to the first rHuEpo administration were 2.4%, 1.6% and 3.6% (CI 1.8 to 3.5, 1.2 to 2.4 and 2.7 to 5.3), respectively.</p></sec><sec id="s2e"><title>Running Performance Assessment</title><p>Two 3,000 m time trials separated by at least one day rest were performed on a 200 m indoor athletic track (Kelvin Hall, Glasgow, UK) pre, post rHuEpo administration and at the end of the study. Verbal encouragement was given with feedback provided for the split time and remaining laps. The best performance on each occasion was used for analysis. The typical error of measurement for time trial performance calculated from the two tests on each phase was 1.3% (CI 1.1 to 1.7). Borg&#x02019;s rating of perceived exertion (RPE) was recorded at the completion of the time trial. Temperature and humidity were recorded using a hygrometer. In addition to the time trial, <inline-formula><inline-graphic xlink:href="pone.0056151.e011.jpg"/></inline-formula> O<sub>2 max</sub> was determined pre, post rHuEpo administration and at the end of the study using an incremental test to exhaustion on a motorised treadmill. Both continuous or discontinuous protocols were used because of other purposes of the study (the speed was increased by 1 km&#x02022;h<sup>&#x02212;1</sup>&#x02022;min<sup>&#x02212;1</sup> or by 2 km&#x02022;h<sup>&#x02212;1</sup> every 3 min with 3 min of active recovery at a walking pace between each bout, respectively). Following a 30 min recovery, <inline-formula><inline-graphic xlink:href="pone.0056151.e012.jpg"/></inline-formula> O<sub>2 max</sub> was verified using a square-wave protocol to exhaustion at a speed equivalent to the end speed attained during the incremental test minus 1 km&#x02022;h<sup>&#x02212;1</sup>
<xref rid="pone.0056151-Kirkeberg1" ref-type="bibr">[21]</xref>, <xref rid="pone.0056151-Pettitt1" ref-type="bibr">[22]</xref>. Gas exchange was measured breath by breath using an automated metabolic gas analysis system (Cosmed Quark b2, Cosmed, Rome, Italy).</p></sec><sec id="s2f"><title>Statistical Analysis</title><p>Individual mean value was calculated when more than one blood sample was collected per week before further analysis. Changes over time in Hb<sub>mass</sub>, blood, red cell and plasma volume were assessed using t-test to determine whether the slope of these parameters was significantly different from zero. Time trial performance, <inline-formula><inline-graphic xlink:href="pone.0056151.e013.jpg"/></inline-formula> O<sub>2 max</sub> and blood parameters data for the key stages of the study were analyzed using repeated measures ANOVA. Relationships between time trial performance, <inline-formula><inline-graphic xlink:href="pone.0056151.e014.jpg"/></inline-formula> O<sub>2 max</sub> and Hb<sub>mass</sub> were assessed using Pearson&#x02019;s product moment correlation coefficients.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Running Performance (<xref ref-type="table" rid="pone-0056151-t001">Table 1</xref>)</title><p>Running performance data of both groups combined (n&#x0200a;=&#x0200a;18) are presented in this paragraph (<xref ref-type="table" rid="pone-0056151-t001">Table 1</xref> for separate groups). Irrespective of running history, time trial performance significantly improved by &#x0223c;6% post administration (10&#x02236;30&#x000b1;1&#x02236;07 min:sec vs. 11&#x02236;08&#x000b1;1&#x02236;15 min:sec, p&#x0003c;0.001) and remained significantly enhanced by &#x0223c;3% 4 weeks after rHuEpo compared to baseline (10&#x02236;46&#x000b1;1&#x02236;13 min:sec vs. 11&#x02236;08&#x000b1;1&#x02236;15 min:sec, p&#x0003c;0.001). RPE did not significantly differ between the time trials (p&#x0003e;0.05). Temperature (19.4&#x000b1;2.8&#x000b0;C) and humidity (46.6&#x000b1;9.0%) remained relatively constant (p&#x0003e;0.05). Relative to baseline, <inline-formula><inline-graphic xlink:href="pone.0056151.e015.jpg"/></inline-formula> O<sub>2 max</sub> significantly increased post administration (60.7&#x000b1;5.8 mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup> vs. 56.0&#x000b1;6.2 mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup>, p&#x0003c;0.001) and remained significantly increased 4 weeks after rHuEpo (58.0&#x000b1;5.6 mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup> vs. 56.0&#x000b1;6.2 mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup>, p&#x0200a;=&#x0200a;0.021). <inline-formula><inline-graphic xlink:href="pone.0056151.e016.jpg"/></inline-formula> O<sub>2 max</sub> was at least moderately correlated with Hb<sub>mass</sub> as well as time trial performance throughout the study (range, r&#x0200a;=&#x0200a;0.48 to r&#x0200a;=&#x0200a;0.88, p&#x0003c;0.05). However, a significant correlation in individual responses compared to baseline between parameter was only observed for Hb<sub>mass</sub> and time trial performance at the end of the study (r&#x0200a;=&#x0200a;&#x02212;0.68, p&#x0200a;=&#x0200a;0.002).</p><table-wrap id="pone-0056151-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0056151.t001</object-id><label>Table 1</label><caption><title>Running 3,000 m time trial performance and maximal oxygen uptake.</title></caption><alternatives><graphic id="pone-0056151-t001-1" xlink:href="pone.0056151.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Group 1</td><td colspan="3" align="left" rowspan="1">Group 2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">End ofrHuEpo</td><td align="left" rowspan="1" colspan="1">End of the study</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">End ofrHuEpo</td><td align="left" rowspan="1" colspan="1">End of the study</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">3,000 m total time (min:sec)</td><td align="left" rowspan="1" colspan="1">10&#x02236;12 (0&#x02236;42)</td><td align="left" rowspan="1" colspan="1">9&#x02236;40* (0&#x02236;37)</td><td align="left" rowspan="1" colspan="1">9&#x02236;53* (0&#x02236;43)</td><td align="left" rowspan="1" colspan="1">12&#x02236;05 (0&#x02236;55)</td><td align="left" rowspan="1" colspan="1">11&#x02236;19* (0&#x02236;53)</td><td align="left" rowspan="1" colspan="1">11&#x02236;39* (0&#x02236;58)</td></tr><tr><td align="left" rowspan="1" colspan="1">1<sup>st</sup> 1,000 m split (min:sec)</td><td align="left" rowspan="1" colspan="1">3&#x02236;16 (0&#x02236;13)</td><td align="left" rowspan="1" colspan="1">3&#x02236;10* (0&#x02236;12)</td><td align="left" rowspan="1" colspan="1">3&#x02236;13 (0&#x02236;13)</td><td align="left" rowspan="1" colspan="1">3&#x02236;53 (0&#x02236;27)</td><td align="left" rowspan="1" colspan="1">3&#x02236;36* (0&#x02236;14)</td><td align="left" rowspan="1" colspan="1">3&#x02236;41 (0&#x02236;20)</td></tr><tr><td align="left" rowspan="1" colspan="1">2<sup>nd</sup> 1,000 m split (min:sec)</td><td align="left" rowspan="1" colspan="1">3&#x02236;26<sup>&#x02020;</sup> (0&#x02236;16)</td><td align="left" rowspan="1" colspan="1">3&#x02236;15*<sup>&#x02020;</sup> (0&#x02236;14)</td><td align="left" rowspan="1" colspan="1">3&#x02236;20<sup>&#x02020;</sup> (0&#x02236;14)</td><td align="left" rowspan="1" colspan="1">4&#x02236;05 (0&#x02236;17)</td><td align="left" rowspan="1" colspan="1">3&#x02236;54<sup>&#x02020;</sup> (0&#x02236;26)</td><td align="left" rowspan="1" colspan="1">3&#x02236;59<sup>&#x02020;</sup> (0&#x02236;20)</td></tr><tr><td align="left" rowspan="1" colspan="1">3<sup>rd</sup> 1,000 m split (min:sec)</td><td align="left" rowspan="1" colspan="1">3&#x02236;29<sup>&#x02020;</sup> (0&#x02236;15)</td><td align="left" rowspan="1" colspan="1">3&#x02236;15* (0&#x02236;13)</td><td align="left" rowspan="1" colspan="1">3&#x02236;20* (0&#x02236;16)</td><td align="left" rowspan="1" colspan="1">4&#x02236;07 (0&#x02236;16)</td><td align="left" rowspan="1" colspan="1">3&#x02236;49*<sup>&#x02020;</sup> (0&#x02236;15)</td><td align="left" rowspan="1" colspan="1">3&#x02236;59<sup>&#x02020;</sup> (0&#x02236;19)</td></tr><tr><td align="left" rowspan="1" colspan="1">RPE scale (6&#x02013;20)</td><td align="left" rowspan="1" colspan="1">18.0 (1.7)</td><td align="left" rowspan="1" colspan="1">18.4 (0.9)</td><td align="left" rowspan="1" colspan="1">19.0 (1.2)</td><td align="left" rowspan="1" colspan="1">17.7 (2.2)</td><td align="left" rowspan="1" colspan="1">18.4 (1.6)</td><td align="left" rowspan="1" colspan="1">18.6 (1.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">O<sub>2 max</sub> (mL&#x02022;min<sup>&#x02212;1</sup>&#x02022;kg<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">60.3 (5.0)</td><td align="left" rowspan="1" colspan="1">64.4* (3.9)</td><td align="left" rowspan="1" colspan="1">61.8 (3.4)</td><td align="left" rowspan="1" colspan="1">51.6 (3.5)</td><td align="left" rowspan="1" colspan="1">57.0* (5.1)</td><td align="left" rowspan="1" colspan="1">54.2* (4.7)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Group 1 included subjects who had a history of running (n&#x0200a;=&#x0200a;9) and group 2 included the other subjects who were involved in other activities (n&#x0200a;=&#x0200a;9). Values are means (SD). Significant differences compared to baseline values are indicated by *<italic>P</italic>&#x0003c;0.05. Significant differences compared to the first 1,000 m split time within the same time trial. <sup>&#x02020;</sup>
<italic>P</italic>&#x0003c;0.05. RPE: Borg&#x02019;s rating of perceived exertion; O<sub>2 max</sub>: Maximal oxygen uptake.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Haematological Parameters and Resting Blood Pressure and Heart Rate (<xref ref-type="table" rid="pone-0056151-t002">Tables 2</xref> and <xref ref-type="table" rid="pone-0056151-t003">3</xref>)</title><p>
<xref ref-type="table" rid="pone-0056151-t002">Table 2</xref> illustrates the changes in the main haematological parameters for five key stages of the study. Relative to baseline values, both haematocrit and haemoglobin concentration gradually increased throughout the rHuEpo administration to reach a maximum approximately one week after the last injection (p&#x0003c;0.001) and remained significantly elevated 4 weeks post rHuEpo administration (p&#x0003c;0.001). Reticulocyte percent increased rapidly after the first two weeks of injections (p&#x0003c;0.001). Nadir with a very low inter-subject variation was reached approximately two weeks after injections ceased, which was significantly lower compared with baseline values (p&#x0003c;0.001). Body mass did not change during the study. rHuEpo administration did not induce any significant changes in resting systolic and diastolic blood pressure as well as in resting heart rate.</p><table-wrap id="pone-0056151-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0056151.t002</object-id><label>Table 2</label><caption><title>Haematocrit, haemoglobin concentration, reticulocytes, haemoglobin mass, blood volumes, carboxyhaemoglobin and body mass before, during and 4 weeks post rHuEpo administration.</title></caption><alternatives><graphic id="pone-0056151-t002-2" xlink:href="pone.0056151.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">Week 2 of rHuEpo</td><td align="left" rowspan="1" colspan="1">End of rHuEpo</td><td align="left" rowspan="1" colspan="1">Week 2 postrHuEpo</td><td align="left" rowspan="1" colspan="1">Week 4 postrHuEpo</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Haematocrit (%)</td><td align="left" rowspan="1" colspan="1">41.9 (1.8)</td><td align="left" rowspan="1" colspan="1">44.7 (2.0)*</td><td align="left" rowspan="1" colspan="1">49.2 (2.0)*</td><td align="left" rowspan="1" colspan="1">47.7 (2.2)*</td><td align="left" rowspan="1" colspan="1">45.1 (1.7)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemoglobin (g&#x02022;dl<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">14.4 (0.7)</td><td align="left" rowspan="1" colspan="1">15.2 (0.7)*</td><td align="left" rowspan="1" colspan="1">16.7 (0.9)*</td><td align="left" rowspan="1" colspan="1">16.1 (0.9)*</td><td align="left" rowspan="1" colspan="1">15.6 (0.7)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Reticulocytes (%)</td><td align="left" rowspan="1" colspan="1">1.07 (0.31)</td><td align="left" rowspan="1" colspan="1">2.57 (0.44)*</td><td align="left" rowspan="1" colspan="1">1.46 (0.41)*</td><td align="left" rowspan="1" colspan="1">0.44 (0.13)*</td><td align="left" rowspan="1" colspan="1">0.55 (0.15)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb<sub>mass</sub> (g&#x02022;kg<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">12.7 (1.2)</td><td align="left" rowspan="1" colspan="1">13.4 (1.3)*</td><td align="left" rowspan="1" colspan="1">15.2 (1.5)*</td><td align="left" rowspan="1" colspan="1">15.1 (1.4)*</td><td align="left" rowspan="1" colspan="1">13.7 (1.1)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb<sub>mass</sub> (g)</td><td align="left" rowspan="1" colspan="1">947 (109)</td><td align="left" rowspan="1" colspan="1">1001 (127)*</td><td align="left" rowspan="1" colspan="1">1131 (131)*</td><td align="left" rowspan="1" colspan="1">1126 (136)*</td><td align="left" rowspan="1" colspan="1">1023 (132)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood volume (L)</td><td align="left" rowspan="1" colspan="1">6.6 (0.9)</td><td align="left" rowspan="1" colspan="1">6.6 (1.0)</td><td align="left" rowspan="1" colspan="1">6.8 (0.8)</td><td align="left" rowspan="1" colspan="1">6.7 (0.9)</td><td align="left" rowspan="1" colspan="1">6.6 (0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Red cell volume (L)</td><td align="left" rowspan="1" colspan="1">2.8 (0.3)</td><td align="left" rowspan="1" colspan="1">2.9 (0.3)*</td><td align="left" rowspan="1" colspan="1">3.3 (0.4)*</td><td align="left" rowspan="1" colspan="1">3.3 (0.4)*</td><td align="left" rowspan="1" colspan="1">3.0 (0.4)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma volume (L)</td><td align="left" rowspan="1" colspan="1">3.8 (0.6)</td><td align="left" rowspan="1" colspan="1">3.7 (0.7)</td><td align="left" rowspan="1" colspan="1">3.5 (0.4)*</td><td align="left" rowspan="1" colspan="1">3.4 (0.6)*</td><td align="left" rowspan="1" colspan="1">3.6 (0.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Carboxyhaemoglobin (%)</td><td align="left" rowspan="1" colspan="1">0.73 (0.15)</td><td align="left" rowspan="1" colspan="1">0.77 (0.16)</td><td align="left" rowspan="1" colspan="1">1.04 (0.19)*</td><td align="left" rowspan="1" colspan="1">1.01 (0.20)*</td><td align="left" rowspan="1" colspan="1">0.65 (0.15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass (kg)</td><td align="left" rowspan="1" colspan="1">75.1 (8.4)</td><td align="left" rowspan="1" colspan="1">74.7 (7.8)</td><td align="left" rowspan="1" colspan="1">75.0 (7.9)</td><td align="left" rowspan="1" colspan="1">74.6 (7.6)</td><td align="left" rowspan="1" colspan="1">74.6 (7.5)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>
<italic>N</italic>&#x0200a;=&#x0200a;19. Values are means (SD). Significant differences compared to baseline values are indicated by *<italic>P</italic>&#x0003c;0.05. Hb<sub>mass</sub>: Haemoglobin mass.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Haemoglobin Mass and Blood Volumes (<xref ref-type="table" rid="pone-0056151-t002">Tables 2</xref>, <xref ref-type="table" rid="pone-0056151-t004">4</xref> and <xref ref-type="fig" rid="pone-0056151-g001">Fig. 1</xref>)</title><p>Relative to baseline, Hb<sub>mass</sub> and plasma volume were significantly increased (p&#x0003c;0.001) and decreased (p&#x0200a;=&#x0200a;0.004) at the end of the rHuEpo administration, respectively. Hb<sub>mass</sub> and red cell volume gradually increased by approximately 40 g&#x02022;wk<sup>&#x02212;1</sup> (p&#x0003c;0.001) and 135 mL&#x02022;wk<sup>&#x02212;1</sup> (p&#x0003c;0.001), respectively (<xref ref-type="fig" rid="pone-0056151-g001">Fig. 1A and 1B</xref>). Plasma volume decreased significantly by approximately 100 mL&#x02022;wk<sup>&#x02212;1</sup> (p&#x0003c;0.001) (<xref ref-type="fig" rid="pone-0056151-g001">Fig. 1C</xref>) while blood volume remained relatively unchanged (p&#x0200a;=&#x0200a;0.32) (<xref ref-type="fig" rid="pone-0056151-g001">Fig. 1D</xref>). From week 1 to week 4 post rHuEpo administration, the rate of decrease in Hb<sub>mass</sub> and red cell volume toward baseline values was similar to that of the increase during administration (<xref ref-type="fig" rid="pone-0056151-g001">Fig. 1A and 1B</xref>) but both Hb<sub>mass</sub> and red cell volume were still significantly elevated 4 weeks post administration compared to baseline (p&#x0003c;0.001). Plasma volume was restored to pre-injection levels 4 weeks post administration (p&#x0200a;=&#x0200a;0.108) (<xref ref-type="fig" rid="pone-0056151-g001">Fig. 1C</xref>).</p><fig id="pone-0056151-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0056151.g001</object-id><label>Figure 1</label><caption><title>Individual changes in Hb<sub>mass</sub> (A), red cell (B), plasma (C) and blood (D) volume.</title><p>Each line corresponds to one subject and each symbol corresponds to the same subject in all figures. Individual mean value was calculated when more than one blood sample was collected per week. The bar graphs represent the mean values of the 19 subjects. The grey bars represent the 4 weeks of rHuEpo administration.</p></caption><graphic xlink:href="pone.0056151.g001"/></fig><table-wrap id="pone-0056151-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0056151.t003</object-id><label>Table 3</label><caption><title>Resting blood pressure and heart rate before, during and 4 weeks post rHuEpo administration.</title></caption><alternatives><graphic id="pone-0056151-t003-3" xlink:href="pone.0056151.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">Week 2 ofrHuEpo</td><td align="left" rowspan="1" colspan="1">End ofrHuEpo</td><td align="left" rowspan="1" colspan="1">Week 2 post rHuEpo</td><td align="left" rowspan="1" colspan="1">Week 4 post rHuEpo</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">128 (9)</td><td align="left" rowspan="1" colspan="1">126 (7)</td><td align="left" rowspan="1" colspan="1">126 (6)</td><td align="left" rowspan="1" colspan="1">126 (7)</td><td align="left" rowspan="1" colspan="1">124 (7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">70 (8)</td><td align="left" rowspan="1" colspan="1">69 (8)</td><td align="left" rowspan="1" colspan="1">69 (7)</td><td align="left" rowspan="1" colspan="1">70 (7)</td><td align="left" rowspan="1" colspan="1">69 (8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beats&#x02022;min<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">62 (8)</td><td align="left" rowspan="1" colspan="1">60 (7)</td><td align="left" rowspan="1" colspan="1">60 (7)</td><td align="left" rowspan="1" colspan="1">59 (7)</td><td align="left" rowspan="1" colspan="1">61 (8)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>
<italic>N</italic>&#x0200a;=&#x0200a;19. Values are means (SD). No significant differences compared to baseline values were observed.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0056151-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0056151.t004</object-id><label>Table 4</label><caption><title>Changes in haemoglobin mass, blood, red cell and plasma volume during and for 4 weeks post rHuEpo administration.</title></caption><alternatives><graphic id="pone-0056151-t004-4" xlink:href="pone.0056151.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">rHuEpo</td><td align="left" rowspan="1" colspan="1">Post rHuEpo</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Haemoglobin mass (g&#x02022;kg<sup>&#x02212;1</sup>&#x02022;wk<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">0.54 (0.46 to 0.63)*</td><td align="left" rowspan="1" colspan="1">&#x02212;0.53 (&#x02212;0.68 to &#x02212;0.38)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood volume (mL&#x02022;kg<sup>&#x02212;1</sup>&#x02022;wk<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">0.34 (&#x02212;0.36 to 1.05)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.60 (&#x02212;1.20 to 0.00)</td></tr><tr><td align="left" rowspan="1" colspan="1">Red cell volume (mL&#x02022;kg<sup>&#x02212;1</sup>&#x02022;wk<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">1.80 (1.50 to 2.10)*</td><td align="left" rowspan="1" colspan="1">&#x02212;1.77 (&#x02212;2.22 to &#x02212;1.33)*</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma volume (mL&#x02022;kg<sup>&#x02212;1</sup>&#x02022;wk<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.30 (&#x02212;1.94 to &#x02212;0.66)*</td><td align="left" rowspan="1" colspan="1">0.50 (0.10 to 0.90)*</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>
<italic>N</italic>&#x0200a;=&#x0200a;19. Values are means (95% confidence interval). Significant changes are indicated by *<italic>P</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title>Carboxyhaemoglobin (<xref ref-type="table" rid="pone-0056151-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0056151-g002">Fig. 2</xref>)</title><p>Relative to baseline values, basal percentage of carboxyhaemoglobin prior to the CO-rebreathing procedure was significantly elevated at the end of the rHuEpo administration (p&#x0003c;0.001). Percentage of carboxyhaemoglobin returned to pre-injection values 4 weeks post rHuEpo administration.</p></sec></sec><sec id="s4"><title>Discussion</title><p>The aim of this study was to investigate the time course of Hb<sub>mass</sub> and related blood parameters as well as changes in running 3,000 m time trial performance following 4 weeks of rHuEpo administration in order to determine whether the augmented <inline-formula><inline-graphic xlink:href="pone.0056151.e017.jpg"/></inline-formula> O<sub>2 max</sub> would translate into actual improvements in running performance in the field. The main findings of this study are that, relative to baseline, running performance was significantly improved following 4 weeks of rHuEpo administration and remained significantly elevated 4 weeks post administration and that these performance effects coincided with significantly rHuEpo-induced elevated <inline-formula><inline-graphic xlink:href="pone.0056151.e018.jpg"/></inline-formula> O<sub>2 max</sub> and Hb<sub>mass</sub>.</p><sec id="s4a"><title>Running Performance</title><p>The effects of rHuEpo on exercise performance have principally been investigated using <inline-formula><inline-graphic xlink:href="pone.0056151.e019.jpg"/></inline-formula> O<sub>2 max</sub> tests. Despite slight differences in the frequency of injections and in the dosage used, rHuEpo administration for 4 to 6 weeks in healthy subjects has been shown to increase <inline-formula><inline-graphic xlink:href="pone.0056151.e020.jpg"/></inline-formula> O<sub>2 max</sub> by approximately 8%, which was confirmed by our observations <xref rid="pone.0056151-Russell1" ref-type="bibr">[23]</xref>, <xref rid="pone.0056151-Audran1" ref-type="bibr">[24]</xref>, <xref rid="pone.0056151-Birkeland1" ref-type="bibr">[25]</xref>, <xref rid="pone.0056151-Berglund1" ref-type="bibr">[26]</xref>, <xref rid="pone.0056151-Wilkerson1" ref-type="bibr">[27]</xref>, <xref rid="pone.0056151-Parisotto1" ref-type="bibr">[28]</xref>, <xref rid="pone.0056151-Connes1" ref-type="bibr">[29]</xref>. However, <inline-formula><inline-graphic xlink:href="pone.0056151.e021.jpg"/></inline-formula> O<sub>2 max</sub> considerably varies among professional athletes <xref rid="pone.0056151-Mujika1" ref-type="bibr">[30]</xref>, <xref rid="pone.0056151-Lucia1" ref-type="bibr">[31]</xref> and <inline-formula><inline-graphic xlink:href="pone.0056151.e022.jpg"/></inline-formula> O<sub>2 max</sub> tests alone may be of little help in determining and ranking exercise performance when athletes of similar endurance ability are compared <xref rid="pone.0056151-Noakes1" ref-type="bibr">[12]</xref>, <xref rid="pone.0056151-Shephard1" ref-type="bibr">[13]</xref>, <xref rid="pone.0056151-Costill1" ref-type="bibr">[14]</xref>, <xref rid="pone.0056151-Levine1" ref-type="bibr">[15]</xref>. Time trial performance more closely reproduces competition conditions and more importantly allows the subjects to choose their own pace. It has previously been observed that blood doping via one unit of autologous blood transfusion, which increased the haematocrit by 5%, improved 10,000 m running performance by approximately one minute in 6 highly trained male distance runners, which corresponded to a &#x0223c;3% improvement <xref rid="pone.0056151-Brien1" ref-type="bibr">[32]</xref>. However, to our knowledge, no study has measured running time trial performance in order to determine whether the augmented <inline-formula><inline-graphic xlink:href="pone.0056151.e023.jpg"/></inline-formula> O<sub>2 max</sub> after rHuEpo administration would translate into actual improvements in performance in the field.</p><p>Relative to baseline, running performance improved post rHuEpo administration and remained enhanced 4 weeks after administration by approximately 6% and 3%, respectively. Following rHuEpo administration, subjects were able to maintain a faster pace throughout the 3,000 m time trial compared to baseline. While the augmented oxygen transport capacity illustrated by the increase in Hb<sub>mass</sub> can explain the increase in <inline-formula><inline-graphic xlink:href="pone.0056151.e024.jpg"/></inline-formula> O<sub>2 max</sub> post rHuEpo administration, it cannot really explain the significant improvement in running performance. Indeed, as oxygen supply and demand are adequately matched during submaximal exercise in healthy men, the rHuEpo-induced augmented oxygen transport capacity cannot be the reason of the improvement in time trial running performance observed in our study <xref rid="pone.0056151-Noakes1" ref-type="bibr">[12]</xref>, <xref rid="pone.0056151-Noakes2" ref-type="bibr">[17]</xref>. In addition, failure to observe a strong correlation between individual changes in <inline-formula><inline-graphic xlink:href="pone.0056151.e025.jpg"/></inline-formula> O<sub>2 max</sub>, Hb<sub>mass</sub> and running performance may imply that rHuEpo administration improves submaximal exercise performance by other mechanisms, although it could also be partly explained by the limited sensitivity of the methods of measurement and by the limitations of the study (see next paragraph). Other mechanisms than the increase in oxygen transport capacity have been proposed to explain the effects of rHuEpo on exercise performance <xref rid="pone.0056151-Boning1" ref-type="bibr">[33]</xref>, <xref rid="pone.0056151-Boning2" ref-type="bibr">[34]</xref>. For instance, it has been demonstrated that self-reported mood, cognitive function and perceived physical condition were improved following rHuEpo administration <xref rid="pone.0056151-Ninot1" ref-type="bibr">[35]</xref>, <xref rid="pone.0056151-Miskowiak1" ref-type="bibr">[36]</xref>. rHuEpo may indeed exert effects in nonhematopoietic tissues including the brain <xref rid="pone.0056151-Jelkmann2" ref-type="bibr">[37]</xref>, <xref rid="pone.0056151-Brines1" ref-type="bibr">[38]</xref>, <xref rid="pone.0056151-Ehrenreich1" ref-type="bibr">[39]</xref>. Admittedly, two different studies conducted by the same research group did not reveal any measurable nonhematopoietic ergogenic effect of rHuEpo on exercise performance and the authors therefore concluded that the increased oxygen carrying capacity is the main if not the only reason why rHuEpo enhances exercise performance in healthy men <xref rid="pone.0056151-Lundby3" ref-type="bibr">[40]</xref>, <xref rid="pone.0056151-Rasmussen1" ref-type="bibr">[41]</xref>. On the other hand, the central governor model can give an alternative view <xref rid="pone.0056151-Noakes1" ref-type="bibr">[12]</xref>. As the perception of effort of the subjects did not change and because the subjects were not limited by an inadequate oxygen supply neither before nor after administration as they ran at submaximal levels, the central governor model would argue that the subjects ran faster after rHuEpo administration because of greater recruitment of motor units allowed by a control mechanism of feed-forward and feedback to the brain [12; especially <xref ref-type="fig" rid="pone-0056151-g002">Fig. 2</xref> of that paper].</p><fig id="pone-0056151-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0056151.g002</object-id><label>Figure 2</label><caption><title>Individual changes in carboxyhaemoglobin.</title><p>Each line corresponds to one subject. Individual mean value was calculated when more than one blood sample was collected per week. The bar graphs represent the mean values of the 19 subjects. The grey bars represent the 4 weeks of rHuEpo administration.</p></caption><graphic xlink:href="pone.0056151.g002"/></fig><p>This study was part of a larger research project funded by WADA and was designed primarily for other purposes. The present study was not blinded, did not include a control group and the subjects, yet involved in endurance activities, were not all runners. As such, we were unable to adequately assess changes in the training load during the study due to the absence of a placebo group and the heterogeneity of sporting/training activity of the subjects. It cannot totally be excluded that the performance enhancements observed may, therefore, be partly due to placebo effect, to an increase in the training load and to an improvement in pacing strategy especially for the non-runners. It was however reassuring that the typical error of measurement for the two time trials conducted on each phase was low and that the amplitude of the improvement observed was well above the confidence interval.</p></sec><sec id="s4b"><title>Haemoglobin Mass and Haematological Parameters</title><p>The level of Hb<sub>mass</sub> prior to the intervention reflected the regular participation in endurance activities of the subjects <xref rid="pone.0056151-Heinicke1" ref-type="bibr">[42]</xref>. Following the first week of rHuEpo administration, Hb<sub>mass</sub> gradually increased and reached its maximum one week after the last injection. The weekly increase of approximately 40 g is equivalent to the haemoglobin contained in one bag of 450 mL stored blood <xref rid="pone.0056151-Morkeberg1" ref-type="bibr">[43]</xref>. The delay of approximately one week between rHuEpo injections and the observed responses in Hb<sub>mass</sub> and red cell volume is explained by the reticulocyte maturation time of 1&#x02013;4 days <xref rid="pone.0056151-Banfi1" ref-type="bibr">[44]</xref>. While normal human red blood cells can theoretically persist in the circulation for approximately 17 weeks <xref rid="pone.0056151-Franco1" ref-type="bibr">[5]</xref>, Hb<sub>mass</sub> and red cell volume started to decrease toward baseline values from approximately the second week post rHuEpo administration with a similar rate to that of the increase during administration. This decrease in Hb<sub>mass</sub> and red cell volume post rHuEpo administration entailed the haemolysis of circulating red blood cells and therefore the release of heme from heamoglobin <xref rid="pone.0056151-Belcher1" ref-type="bibr">[45]</xref>. The heme degradation is catalyzed by heme oxygenase and generates one molecule of CO per molecule of heme oxidized <xref rid="pone.0056151-Ryter1" ref-type="bibr">[46]</xref>. The CO produced by heme metabolism represents more than 85% of the endogenous CO production in healthy non-smoking subjects <xref rid="pone.0056151-Ryter1" ref-type="bibr">[46]</xref>. Although measurement of blood carboxyhaemoglobin is influenced by environmental factors such as air pollution <xref rid="pone.0056151-Franco1" ref-type="bibr">[5]</xref>, carboxyhaemoglobin can be used as an index of haemolysis <xref rid="pone.0056151-Engel1" ref-type="bibr">[47]</xref>. Indeed, basal carboxyhaemoglobin levels increased at the end of the rHuEpo administration and remained elevated for 2 weeks post administration reflecting accelerated haemolysis. Despite being only an indirect marker, these results are in agreement with the negative regulation of red cell mass by neocytolysis when supraphysiologic red cell mass and endogenous erythropoietin suppression occur (induced by rHuEpo administration, for instance) <xref rid="pone.0056151-Rice2" ref-type="bibr">[7]</xref>, <xref rid="pone.0056151-Chang1" ref-type="bibr">[8]</xref>. In addition, this study confirmed that 4 weeks of rHuEpo administration sufficient to induce a significant increase in haematocrit did not increase resting blood pressure in healthy subjects when blood pressure was assessed by standard techniques compared to intra-arterial pressure transducers <xref rid="pone.0056151-Lundby3" ref-type="bibr">[40]</xref>. This study also demonstrates that the optimized CO-rebreathing method performed weekly for ten weeks is safe and well tolerated by healthy subjects.</p></sec><sec id="s4c"><title>Plasma Volume</title><p>Apart from confirming previous observations that rHuEpo administration increases haemoglobin concentration by increasing Hb<sub>mass</sub> and by decreasing plasma volume <xref rid="pone.0056151-Lundby1" ref-type="bibr">[2]</xref>, <xref rid="pone.0056151-Olsen1" ref-type="bibr">[3]</xref>, the present study showed that plasma volume returned to pre-injection values only approximately 4 weeks post rHuEpo administration. Previous studies have concluded that plasma volume returned rather rapidly toward baseline value thus restoring pre-administration haemoglobin concentration values without affecting red cell volume <xref rid="pone.0056151-Olsen1" ref-type="bibr">[3]</xref>, <xref rid="pone.0056151-Lundby2" ref-type="bibr">[4]</xref>. Olsen et al. <xref rid="pone.0056151-Olsen1" ref-type="bibr">[3]</xref> used injections of 5000 IU rHuEpo administered every second day for 2 weeks and thereafter only once a week for the 2 consecutive weeks to demonstrate that rHuEpo down-regulates the renin-angiotensin-aldosterone system as well as the rate of proximal renal tubular reabsorption and glomerular filtration. The longer and more contrasted rHuEpo administration regimen used in the present study with a more abrupt erythropoiesis stimulation termination may have induced a more profound down-regulation of the renin-angiotensin-aldosterone system and therefore, may explain why plasma volume had not been restored until 4 weeks after rHuEpo administration. In agreement with previous findings which used a similar rHuEpo regimen than the present study, pre-injection haemoglobin concentration values were not restored 4 weeks post administration <xref rid="pone.0056151-Parisotto1" ref-type="bibr">[28]</xref>.</p><p>In conclusion, relative to baseline, running performance was significantly improved following 4 weeks of rHuEpo administration in trained men and remained significantly elevated 4 weeks after administration by approximately 6% and 3%, respectively. These performance effects coincided with significantly rHuEpo-induced elevated <inline-formula><inline-graphic xlink:href="pone.0056151.e026.jpg"/></inline-formula> O<sub>2 max</sub> and Hb<sub>mass</sub>.</p></sec></sec></body><back><ack><p>The authors wish to specially thank the subjects for their participation and cooperation. We would like also to thank students who helped with data collection as well as the members of the WADA Project (08C19YP) Steering Committee and especially Professor T.D. Noakes, Dr. S. Padmanabhan and Dr. G. Gmeiner.</p></ack><ref-list><title>References</title><ref id="pone.0056151-Jelkmann1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Jelkmann</surname><given-names>W</given-names></name> (<year>2011</year>) <article-title>Regulation of erythropoietin production</article-title>. <source>J Physiol</source>
<volume>589</volume>: <fpage>1251</fpage>&#x02013;<lpage>1258</lpage>.<pub-id pub-id-type="pmid">21078592</pub-id></mixed-citation></ref><ref id="pone.0056151-Lundby1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Lundby</surname><given-names>C</given-names></name>, <name><surname>Thomsen</surname><given-names>JJ</given-names></name>, <name><surname>Boushel</surname><given-names>R</given-names></name>, <name><surname>Koskolou</surname><given-names>M</given-names></name>, <name><surname>Warberg</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume</article-title>. <source>J Physiol</source>
<volume>578</volume>: <fpage>309</fpage>&#x02013;<lpage>314</lpage>.<pub-id pub-id-type="pmid">17095558</pub-id></mixed-citation></ref><ref id="pone.0056151-Olsen1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Olsen</surname><given-names>NV</given-names></name>, <name><surname>Aachmann-Andersen</surname><given-names>NJ</given-names></name>, <name><surname>Oturai</surname><given-names>P</given-names></name>, <name><surname>Munch-Andersen</surname><given-names>T</given-names></name>, <name><surname>Borno</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans</article-title>. <source>J Physiol</source>
<volume>589</volume>: <fpage>1273</fpage>&#x02013;<lpage>1281</lpage>.<pub-id pub-id-type="pmid">20724370</pub-id></mixed-citation></ref><ref id="pone.0056151-Lundby2"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Lundby</surname><given-names>C</given-names></name>, <name><surname>Olsen</surname><given-names>NV</given-names></name> (<year>2011</year>) <article-title>Effects of recombinant human erythropoietin in normal humans</article-title>. <source>J Physiol</source>
<volume>589</volume>: <fpage>1265</fpage>&#x02013;<lpage>1271</lpage>.<pub-id pub-id-type="pmid">20807784</pub-id></mixed-citation></ref><ref id="pone.0056151-Franco1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Franco</surname><given-names>RS</given-names></name> (<year>2009</year>) <article-title>The measurement and importance of red cell survival</article-title>. <source>Am J Hematol</source>
<volume>84</volume>: <fpage>109</fpage>&#x02013;<lpage>114</lpage>.<pub-id pub-id-type="pmid">19025796</pub-id></mixed-citation></ref><ref id="pone.0056151-Rice1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Rice</surname><given-names>L</given-names></name>, <name><surname>Ruiz</surname><given-names>W</given-names></name>, <name><surname>Driscoll</surname><given-names>T</given-names></name>, <name><surname>Whitley</surname><given-names>CE</given-names></name>, <name><surname>Tapia</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass</article-title>. <source>Ann Intern Med</source>
<volume>134</volume>: <fpage>652</fpage>&#x02013;<lpage>656</lpage>.<pub-id pub-id-type="pmid">11304105</pub-id></mixed-citation></ref><ref id="pone.0056151-Rice2"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Rice</surname><given-names>L</given-names></name>, <name><surname>Alfrey</surname><given-names>CP</given-names></name> (<year>2005</year>) <article-title>The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations</article-title>. <source>Cell Physiol Biochem</source>
<volume>15</volume>: <fpage>245</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">16037689</pub-id></mixed-citation></ref><ref id="pone.0056151-Chang1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>CC</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Modi</surname><given-names>K</given-names></name>, <name><surname>Awar</surname><given-names>O</given-names></name>, <name><surname>Alfrey</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Changes of red blood cell surface markers in a blood doping model of neocytolysis</article-title>. <source>J Investig Med</source>
<volume>57</volume>: <fpage>650</fpage>&#x02013;<lpage>654</lpage>.</mixed-citation></ref><ref id="pone.0056151-Alfrey1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Alfrey</surname><given-names>CP</given-names></name>, <name><surname>Rice</surname><given-names>L</given-names></name>, <name><surname>Udden</surname><given-names>MM</given-names></name>, <name><surname>Driscoll</surname><given-names>TB</given-names></name> (<year>1997</year>) <article-title>Neocytolysis: physiological down-regulator of red-cell mass</article-title>. <source>Lancet</source>
<volume>349</volume>: <fpage>1389</fpage>&#x02013;<lpage>1390</lpage>.<pub-id pub-id-type="pmid">9149714</pub-id></mixed-citation></ref><ref id="pone.0056151-Schmidt1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Schmidt</surname><given-names>W</given-names></name>, <name><surname>Prommer</surname><given-names>N</given-names></name> (<year>2005</year>) <article-title>The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely</article-title>. <source>Eur J Appl Physiol</source>
<volume>95</volume>: <fpage>486</fpage>&#x02013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">16222540</pub-id></mixed-citation></ref><ref id="pone.0056151-Durussel1"><label>11</label><mixed-citation publication-type="other">Durussel J, Ross R, Raj Kodi P, Daskalaki E, Pantazis T, <etal>et al</etal>.. (2011) Precision of the optimized carbon monoxide rebreathing method to determine total haemoglobin mass and blood volume. Eur J Sport Sci.</mixed-citation></ref><ref id="pone.0056151-Noakes1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Noakes</surname><given-names>TD</given-names></name> (<year>2008</year>) <article-title>Testing for maximum oxygen consumption has produced a brainless model of human exercise performance</article-title>. <source>Br J Sports Med</source>
<volume>42</volume>: <fpage>551</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">18424484</pub-id></mixed-citation></ref><ref id="pone.0056151-Shephard1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Shephard</surname><given-names>RJ</given-names></name> (<year>2009</year>) <article-title>Is the measurement of maximal oxygen intake passe?</article-title>
<source>Br J Sports Med</source>
<volume>43</volume>: <fpage>83</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">18718973</pub-id></mixed-citation></ref><ref id="pone.0056151-Costill1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Costill</surname><given-names>DL</given-names></name>, <name><surname>Thomason</surname><given-names>H</given-names></name>, <name><surname>Roberts</surname><given-names>E</given-names></name> (<year>1973</year>) <article-title>Fractional utilization of the aerobic capacity during distance running</article-title>. <source>Med Sci Sports</source>
<volume>5</volume>: <fpage>248</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">4774203</pub-id></mixed-citation></ref><ref id="pone.0056151-Levine1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Levine</surname><given-names>BD</given-names></name>, <name><surname>Stray-Gundersen</surname><given-names>J</given-names></name> (<year>1992</year>) <article-title>A practical approach to altitude training: where to live and train for optimal performance enhancement</article-title>. <source>International journal of sports medicine</source>
<volume>13</volume> Suppl 1<fpage>S209</fpage>&#x02013;<lpage>212</lpage>.<pub-id pub-id-type="pmid">1483778</pub-id></mixed-citation></ref><ref id="pone.0056151-Thomsen1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Thomsen</surname><given-names>JJ</given-names></name>, <name><surname>Rentsch</surname><given-names>RL</given-names></name>, <name><surname>Robach</surname><given-names>P</given-names></name>, <name><surname>Calbet</surname><given-names>JA</given-names></name>, <name><surname>Boushel</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity</article-title>. <source>Eur J Appl Physiol</source>
<volume>101</volume>: <fpage>481</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">17668232</pub-id></mixed-citation></ref><ref id="pone.0056151-Noakes2"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Noakes</surname><given-names>TD</given-names></name> (<year>2008</year>) <article-title>Mechanism by which rHuEPO improves submaximal exercise performance</article-title>. <source>Eur J Appl Physiol</source>
<volume>103</volume>: <fpage>485</fpage>.<pub-id pub-id-type="pmid">18368420</pub-id></mixed-citation></ref><ref id="pone.0056151-Millet1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Millet</surname><given-names>GP</given-names></name>, <name><surname>Roels</surname><given-names>B</given-names></name>, <name><surname>Schmitt</surname><given-names>L</given-names></name>, <name><surname>Woorons</surname><given-names>X</given-names></name>, <name><surname>Richalet</surname><given-names>JP</given-names></name> (<year>2010</year>) <article-title>Combining hypoxic methods for peak performance</article-title>. <source>Sports medicine</source>
<volume>40</volume>: <fpage>1</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">20020784</pub-id></mixed-citation></ref><ref id="pone.0056151-Laursen1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Laursen</surname><given-names>PB</given-names></name>, <name><surname>Francis</surname><given-names>GT</given-names></name>, <name><surname>Abbiss</surname><given-names>CR</given-names></name>, <name><surname>Newton</surname><given-names>MJ</given-names></name>, <name><surname>Nosaka</surname><given-names>K</given-names></name> (<year>2007</year>) <article-title>Reliability of time-to-exhaustion versus time-trial running tests in runners</article-title>. <source>Med Sci Sports Exerc</source>
<volume>39</volume>: <fpage>1374</fpage>&#x02013;<lpage>1379</lpage>.<pub-id pub-id-type="pmid">17762371</pub-id></mixed-citation></ref><ref id="pone.0056151-Ahlgrim1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Ahlgrim</surname><given-names>C</given-names></name>, <name><surname>Pottgiesser</surname><given-names>T</given-names></name>, <name><surname>Robinson</surname><given-names>N</given-names></name>, <name><surname>Sottas</surname><given-names>PE</given-names></name>, <name><surname>Ruecker</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Are 10 min of seating enough to guarantee stable haemoglobin and haematocrit readings for the athlete&#x02019;s biological passport?</article-title>
<source>Int J Lab Hematol</source>
<volume>32</volume>: <fpage>1</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0056151-Kirkeberg1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Kirkeberg</surname><given-names>JM</given-names></name>, <name><surname>Dalleck</surname><given-names>LC</given-names></name>, <name><surname>Kamphoff</surname><given-names>CS</given-names></name>, <name><surname>Pettitt</surname><given-names>RW</given-names></name> (<year>2011</year>) <article-title>Validity of 3 protocols for verifying VO2 max</article-title>. <source>Int J Sports Med</source>
<volume>32</volume>: <fpage>266</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">21271494</pub-id></mixed-citation></ref><ref id="pone.0056151-Pettitt1"><label>22</label><mixed-citation publication-type="other">Pettitt RW, Clark IE, Ebner SM, Sedgeman DT, Murray SR (2012) Gas Exchange Threshold and VO2max Testing for Athletes: An Update. J Strength Cond Res.</mixed-citation></ref><ref id="pone.0056151-Russell1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Russell</surname><given-names>G</given-names></name>, <name><surname>Gore</surname><given-names>CJ</given-names></name>, <name><surname>Ashenden</surname><given-names>MJ</given-names></name>, <name><surname>Parisotto</surname><given-names>R</given-names></name>, <name><surname>Hahn</surname><given-names>AG</given-names></name> (<year>2002</year>) <article-title>Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise</article-title>. <source>Eur J Appl Physiol</source>
<volume>86</volume>: <fpage>442</fpage>&#x02013;<lpage>449</lpage>.<pub-id pub-id-type="pmid">11882931</pub-id></mixed-citation></ref><ref id="pone.0056151-Audran1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Audran</surname><given-names>M</given-names></name>, <name><surname>Gareau</surname><given-names>R</given-names></name>, <name><surname>Matecki</surname><given-names>S</given-names></name>, <name><surname>Durand</surname><given-names>F</given-names></name>, <name><surname>Chenard</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Effects of erythropoietin administration in training athletes and possible indirect detection in doping control</article-title>. <source>Med Sci Sports Exerc</source>
<volume>31</volume>: <fpage>639</fpage>&#x02013;<lpage>645</lpage>.<pub-id pub-id-type="pmid">10331881</pub-id></mixed-citation></ref><ref id="pone.0056151-Birkeland1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Birkeland</surname><given-names>KI</given-names></name>, <name><surname>Stray-Gundersen</surname><given-names>J</given-names></name>, <name><surname>Hemmersbach</surname><given-names>P</given-names></name>, <name><surname>Hallen</surname><given-names>J</given-names></name>, <name><surname>Haug</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Effect of rhEPO administration on serum levels of sTfR and cycling performance</article-title>. <source>Med Sci Sports Exerc</source>
<volume>32</volume>: <fpage>1238</fpage>&#x02013;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">10912888</pub-id></mixed-citation></ref><ref id="pone.0056151-Berglund1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Berglund</surname><given-names>B</given-names></name>, <name><surname>Ekblom</surname><given-names>B</given-names></name> (<year>1991</year>) <article-title>Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men</article-title>. <source>J Intern Med</source>
<volume>229</volume>: <fpage>125</fpage>&#x02013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">1997637</pub-id></mixed-citation></ref><ref id="pone.0056151-Wilkerson1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Wilkerson</surname><given-names>DP</given-names></name>, <name><surname>Rittweger</surname><given-names>J</given-names></name>, <name><surname>Berger</surname><given-names>NJ</given-names></name>, <name><surname>Naish</surname><given-names>PF</given-names></name>, <name><surname>Jones</surname><given-names>AM</given-names></name> (<year>2005</year>) <article-title>Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans</article-title>. <source>J Physiol</source>
<volume>568</volume>: <fpage>639</fpage>&#x02013;<lpage>652</lpage>.<pub-id pub-id-type="pmid">16081477</pub-id></mixed-citation></ref><ref id="pone.0056151-Parisotto1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Parisotto</surname><given-names>R</given-names></name>, <name><surname>Gore</surname><given-names>CJ</given-names></name>, <name><surname>Emslie</surname><given-names>KR</given-names></name>, <name><surname>Ashenden</surname><given-names>MJ</given-names></name>, <name><surname>Brugnara</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes</article-title>. <source>Haematologica</source>
<volume>85</volume>: <fpage>564</fpage>&#x02013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">10870111</pub-id></mixed-citation></ref><ref id="pone.0056151-Connes1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Connes</surname><given-names>P</given-names></name>, <name><surname>Perrey</surname><given-names>S</given-names></name>, <name><surname>Varray</surname><given-names>A</given-names></name>, <name><surname>Prefaut</surname><given-names>C</given-names></name>, <name><surname>Caillaud</surname><given-names>C</given-names></name> (<year>2003</year>) <article-title>Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment</article-title>. <source>Pflugers Arch</source>
<volume>447</volume>: <fpage>231</fpage>&#x02013;<lpage>238</lpage>.<pub-id pub-id-type="pmid">14551773</pub-id></mixed-citation></ref><ref id="pone.0056151-Mujika1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Mujika</surname><given-names>I</given-names></name>, <name><surname>Padilla</surname><given-names>S</given-names></name> (<year>2001</year>) <article-title>Physiological and performance characteristics of male professional road cyclists</article-title>. <source>Sports Med</source>
<volume>31</volume>: <fpage>479</fpage>&#x02013;<lpage>487</lpage>.<pub-id pub-id-type="pmid">11428685</pub-id></mixed-citation></ref><ref id="pone.0056151-Lucia1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Lucia</surname><given-names>A</given-names></name>, <name><surname>Hoyos</surname><given-names>J</given-names></name>, <name><surname>Perez</surname><given-names>M</given-names></name>, <name><surname>Santalla</surname><given-names>A</given-names></name>, <name><surname>Chicharro</surname><given-names>JL</given-names></name> (<year>2002</year>) <article-title>Inverse relationship between VO2max and economy/efficiency in world-class cyclists</article-title>. <source>Med Sci Sports Exerc</source>
<volume>34</volume>: <fpage>2079</fpage>&#x02013;<lpage>2084</lpage>.<pub-id pub-id-type="pmid">12471319</pub-id></mixed-citation></ref><ref id="pone.0056151-Brien1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Brien</surname><given-names>AJ</given-names></name>, <name><surname>Simon</surname><given-names>TL</given-names></name> (<year>1987</year>) <article-title>The effects of red blood cell infusion on 10-km race time</article-title>. <source>JAMA</source>
<volume>257</volume>: <fpage>2761</fpage>&#x02013;<lpage>2765</lpage>.<pub-id pub-id-type="pmid">3573270</pub-id></mixed-citation></ref><ref id="pone.0056151-Boning1"><label>33</label><mixed-citation publication-type="other">Boning D, Maassen N, Pries A (2008) No proof for augmented arterial oxygen content as only factor influencing exercise capacity after Epo doping. J Appl Physiol 105: 1988; author reply 1989.</mixed-citation></ref><ref id="pone.0056151-Boning2"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Boning</surname><given-names>D</given-names></name>, <name><surname>Maassen</surname><given-names>N</given-names></name>, <name><surname>Pries</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>The hematocrit paradox&#x02013;how does blood doping really work?</article-title>
<source>Int J Sports Med</source>
<volume>32</volume>: <fpage>242</fpage>&#x02013;<lpage>246</lpage>.<pub-id pub-id-type="pmid">20617487</pub-id></mixed-citation></ref><ref id="pone.0056151-Ninot1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Ninot</surname><given-names>G</given-names></name>, <name><surname>Connes</surname><given-names>P</given-names></name>, <name><surname>Caillaud</surname><given-names>C</given-names></name> (<year>2006</year>) <article-title>Effects of recombinant human erythropoietin injections on physical self in endurance athletes</article-title>. <source>J Sports Sci</source>
<volume>24</volume>: <fpage>383</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">16492602</pub-id></mixed-citation></ref><ref id="pone.0056151-Miskowiak1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Miskowiak</surname><given-names>K</given-names></name>, <name><surname>Inkster</surname><given-names>B</given-names></name>, <name><surname>Selvaraj</surname><given-names>S</given-names></name>, <name><surname>Wise</surname><given-names>R</given-names></name>, <name><surname>Goodwin</surname><given-names>GM</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration</article-title>. <source>Neuropsychopharmacology</source>
<volume>33</volume>: <fpage>611</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">17473836</pub-id></mixed-citation></ref><ref id="pone.0056151-Jelkmann2"><label>37</label><mixed-citation publication-type="other">Jelkmann W, Depping R, Metzen E (2009) Nonhematopoietic effects of erythropoiesis-stimulating agents. In: Elliott SG, Foote M, Molineux G, editors. Erythropoietin, Erythropoietic Factores, and Erythropoiesis. Basel: Birkh&#x000e4;user. 299&#x02013;317.</mixed-citation></ref><ref id="pone.0056151-Brines1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Brines</surname><given-names>M</given-names></name>, <name><surname>Cerami</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>Emerging biological roles for erythropoietin in the nervous system</article-title>. <source>Nat Rev Neurosci</source>
<volume>6</volume>: <fpage>484</fpage>&#x02013;<lpage>494</lpage>.<pub-id pub-id-type="pmid">15928718</pub-id></mixed-citation></ref><ref id="pone.0056151-Ehrenreich1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Ehrenreich</surname><given-names>H</given-names></name>, <name><surname>Bartels</surname><given-names>C</given-names></name>, <name><surname>Sargin</surname><given-names>D</given-names></name>, <name><surname>Stawicki</surname><given-names>S</given-names></name>, <name><surname>Krampe</surname><given-names>H</given-names></name> (<year>2008</year>) <article-title>Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition</article-title>. <source>J Ren Nutr</source>
<volume>18</volume>: <fpage>146</fpage>&#x02013;<lpage>153</lpage>.<pub-id pub-id-type="pmid">18089462</pub-id></mixed-citation></ref><ref id="pone.0056151-Lundby3"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Lundby</surname><given-names>C</given-names></name>, <name><surname>Robach</surname><given-names>P</given-names></name>, <name><surname>Boushel</surname><given-names>R</given-names></name>, <name><surname>Thomsen</surname><given-names>JJ</given-names></name>, <name><surname>Rasmussen</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport?</article-title>
<source>J Appl Physiol</source>
<volume>105</volume>: <fpage>581</fpage>&#x02013;<lpage>587</lpage>.<pub-id pub-id-type="pmid">18535134</pub-id></mixed-citation></ref><ref id="pone.0056151-Rasmussen1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Rasmussen</surname><given-names>P</given-names></name>, <name><surname>Foged</surname><given-names>EM</given-names></name>, <name><surname>Krogh-Madsen</surname><given-names>R</given-names></name>, <name><surname>Nielsen</surname><given-names>J</given-names></name>, <name><surname>Nielsen</surname><given-names>TR</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Effects of erythropoietin administration on cerebral metabolism and exercise capacity in men</article-title>. <source>J Appl Physiol</source>
<volume>109</volume>: <fpage>476</fpage>&#x02013;<lpage>483</lpage>.<pub-id pub-id-type="pmid">20522733</pub-id></mixed-citation></ref><ref id="pone.0056151-Heinicke1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Heinicke</surname><given-names>K</given-names></name>, <name><surname>Wolfarth</surname><given-names>B</given-names></name>, <name><surname>Winchenbach</surname><given-names>P</given-names></name>, <name><surname>Biermann</surname><given-names>B</given-names></name>, <name><surname>Schmid</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Blood volume and hemoglobin mass in elite athletes of different disciplines</article-title>. <source>Int J Sports Med</source>
<volume>22</volume>: <fpage>504</fpage>&#x02013;<lpage>512</lpage>.<pub-id pub-id-type="pmid">11590477</pub-id></mixed-citation></ref><ref id="pone.0056151-Morkeberg1"><label>43</label><mixed-citation publication-type="other">Morkeberg J, Sharpe K, Belhage B, Damsgaard R, Schmidt W, <etal>et al</etal>.. (2009) Detecting autologous blood transfusions: a comparison of three passport approaches and four blood markers. Scand J Med Sci Sports: 1&#x02013;9.</mixed-citation></ref><ref id="pone.0056151-Banfi1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Banfi</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Reticulocytes in sports medicine</article-title>. <source>Sports Med</source>
<volume>38</volume>: <fpage>187</fpage>&#x02013;<lpage>211</lpage>.<pub-id pub-id-type="pmid">18278982</pub-id></mixed-citation></ref><ref id="pone.0056151-Belcher1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Belcher</surname><given-names>JD</given-names></name>, <name><surname>Beckman</surname><given-names>JD</given-names></name>, <name><surname>Balla</surname><given-names>G</given-names></name>, <name><surname>Balla</surname><given-names>J</given-names></name>, <name><surname>Vercellotti</surname><given-names>G</given-names></name> (<year>2010</year>) <article-title>Heme degradation and vascular injury</article-title>. <source>Antioxid Redox Signal</source>
<volume>12</volume>: <fpage>233</fpage>&#x02013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">19697995</pub-id></mixed-citation></ref><ref id="pone.0056151-Ryter1"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Ryter</surname><given-names>SW</given-names></name>, <name><surname>Otterbein</surname><given-names>LE</given-names></name> (<year>2004</year>) <article-title>Carbon monoxide in biology and medicine</article-title>. <source>Bioessays</source>
<volume>26</volume>: <fpage>270</fpage>&#x02013;<lpage>280</lpage>.<pub-id pub-id-type="pmid">14988928</pub-id></mixed-citation></ref><ref id="pone.0056151-Engel1"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Engel</surname><given-names>RR</given-names></name>, <name><surname>Rodkey</surname><given-names>FL</given-names></name>, <name><surname>Krill</surname><given-names>CE</given-names><suffix>Jr</suffix></name> (<year>1971</year>) <article-title>Carboxyhemoglobin levels as an index of hemolysis</article-title>. <source>Pediatrics</source>
<volume>47</volume>: <fpage>723</fpage>&#x02013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">5104458</pub-id></mixed-citation></ref></ref-list></back></article>